Is telehealth allowed to prescribe Mounjaro in Texas?

If you’ve been researching GLP-1 medications like Wegovy, Ozempic, or Mounjaro for weight loss, you’ve probably wondered: Can I actually get these prescribed through telehealth? The short answer is yes—in most cases, you can legally receive a prescription for these medications via telemedicine in the United States.

But as with many healthcare questions, the details matter. State regulations vary, provider qualifications differ, and understanding what’s required can help you navigate the process smoothly and safely. This guide breaks down everything you need to know about accessing weight loss medications through telehealth in 2025.

Understanding the Legal Landscape for Telehealth Prescribing

Federal Law: The Good News for GLP-1 Medications

Here’s an important distinction that clears up a lot of confusion: GLP-1 weight loss medications are not controlled substances. This matters because federal law—specifically the Ryan Haight Act—requires an in-person examination before prescribing controlled substances via telemedicine. Since medications like Wegovy (semaglutide), Ozempic (semaglutide), and Mounjaro (tirzepatide) are unscheduled drugs, this federal restriction simply doesn’t apply to them.

During the COVID-19 pandemic, the Drug Enforcement Administration (DEA) temporarily waived even the controlled substance restrictions to expand telehealth access. As of December 2025, these flexibilities have been extended through December 31, 2025, and signals suggest further extensions are likely for 2026. But the key takeaway is this: the telehealth prescribing of non-controlled medications like GLP-1 agonists has remained consistently legal throughout and beyond the pandemic.

What This Means for You

A licensed healthcare provider can evaluate you through a video consultation, review your medical history, and send a prescription electronically to your pharmacy—all without requiring an initial in-person visit under federal law. This has opened the door for millions of Americans to access obesity treatment who might otherwise face barriers like limited local specialists, transportation challenges, or time constraints.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

State-Specific Requirements: Where Things Get Nuanced

While federal law provides the foundation, state regulations add important layers that affect how telehealth weight loss care works in practice. Some states have embraced telehealth with minimal restrictions, while others require specific protocols to ensure patient safety.

States Requiring Initial In-Person Exams

Several states mandate that patients complete an in-person physical examination before or shortly after starting telehealth treatment for weight loss medications:

Arkansas maintains some of the strictest telemedicine regulations in the country. The state requires an initial in-person encounter to establish a valid patient-provider relationship before prescribing weight loss medications via telehealth. Proposals to ease these restrictions have been under review as of late 2025.

Georgia requires an initial in-person examination before prescribing obesity medications through telehealth. However, the state made significant progress in 2024 by passing legislation (effective July 1, 2024) that allows nurse practitioners and physician assistants to prescribe Schedule II controlled substances with proper physician delegation—a step toward broader prescriptive access.

Delaware mandates an initial physical examination in person before a provider can prescribe weight loss medications via telehealth, though follow-up visits can be conducted remotely.

Texas follows a standard of care that typically requires an initial in-person exam for weight loss treatment, though this is more of a professional practice guideline than an absolute legal prohibition. Texas also requires physician delegation agreements for NPs and PAs, making the state’s oversight particularly strict.

South Carolina, Mississippi, and North Dakota similarly expect an initial hands-on evaluation before telehealth prescribing of obesity medications, reflecting a more conservative approach to remote care.

States with Robust Telehealth Access

On the other end of the spectrum, many states have fully embraced telehealth for obesity treatment:

California explicitly permits telehealth examinations to establish patient-provider relationships without requiring in-person visits. The state also grants nurse practitioners full independent practice authority after gaining three years of experience, expanding access to care.

Washington State has been a telehealth pioneer with no in-person requirements for weight loss medication prescribing. The state’s My Health My Data Act (2023) does add important privacy protections for telehealth patients, which is particularly relevant given the sensitive nature of weight-loss data.

New York allows providers to prescribe GLP-1 medications entirely through telehealth, and NPs can practice independently after completing 3,600 hours of supervised practice. The state’s mandatory e-prescribing requirements (in place since 2016) also streamline the prescription process.

Illinois enacted permanent telehealth legislation that places no special barriers on weight loss prescribing beyond standard medical practice. The state mandates electronic prescribing for all medications, making the process efficient and trackable.

Connecticut, Pennsylvania, Utah, and Virginia also permit telehealth prescribing, though Virginia does require an initial comprehensive evaluation (including physical exam and labs) and a follow-up within 30 days of starting therapy—a reasonable middle ground that balances access with safety.

States with Specialized Requirements

Some states allow telehealth prescribing but add specific clinical requirements:

Florida permits telehealth for obesity medications but requires that patients have a BMI of 30 or greater (or 27+ with comorbidities) and be seen at least once every three months during treatment. These requirements reflect the state’s focus on ongoing monitoring and appropriate use.

New Jersey has particularly detailed regulations: providers must conduct a comprehensive initial work-up including physical examination, laboratory tests, psychological screening, and development of a personalized diet and exercise plan. Informed consent specifically covering weight-loss medication risks must also be documented.

Connecticut similarly requires that obesity treatment include behavioral counseling and a documented diet and exercise plan alongside any medication therapy.

Who Can Prescribe Weight Loss Medications via Telehealth?

Understanding provider qualifications is essential, as you may encounter different types of clinicians in telehealth settings.

Medical Doctors (MDs) and Doctors of Osteopathy (DOs)

All states allow fully licensed MDs and DOs to prescribe GLP-1 weight loss medications via telehealth, provided they are licensed in the state where the patient is physically located during the consultation. This is straightforward and universally accepted.

Nurse Practitioners (NPs)

Nurse practitioners play an increasingly important role in telehealth weight management, but their prescribing authority varies significantly by state:

Full Practice Authority States (34 states plus DC as of 2025): NPs can evaluate patients, diagnose conditions, and prescribe medications independently without physician oversight after meeting experience requirements. States in this category include Washington, California, New York, Arizona, Colorado, Maryland, and many others. This independence often comes after 2-3 years of supervised practice.

Reduced Practice States: NPs can prescribe but must have a collaborative agreement or practice protocol with a supervising physician. States like Florida, Georgia (though expanding), Texas, Pennsylvania, and Illinois fall into this category. The physician doesn’t need to be on-site but must be available for consultation.

Restricted Practice States (increasingly rare): Very few states now severely restrict NP prescribing. Even traditionally conservative states have been moving toward collaborative models rather than outright prohibition.

Physician Assistants (PAs)

PAs can prescribe weight loss medications in all states, but like NPs, they typically work under physician supervision or collaborative agreements. The degree of autonomy varies, with some states allowing significant independence while others require closer oversight.

What This Means for Patients

When you connect with a telehealth provider for weight loss treatment, you might see an MD, DO, NP, or PA. This is completely normal and legal, as long as that provider is properly licensed in your state and operating within their scope of practice.

At Klarity Health, we ensure all our providers are appropriately credentialed and licensed in the states where they practice. Whether you’re working with a physician or an advanced practice provider, you can feel confident in the quality and legality of your care.

The Medications: What Can Be Prescribed Through Telehealth?

FDA-Approved Weight Loss Medications

Wegovy (semaglutide 2.4mg) is FDA-approved specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. It’s administered as a once-weekly subcutaneous injection.

Ozempic (semaglutide 0.5-1mg) is FDA-approved for type 2 diabetes but is frequently prescribed off-label for weight loss. When prescribed for weight management, providers must document the off-label use and obtain informed consent. Despite having the same active ingredient as Wegovy, Ozempic is dosed differently and primarily indicated for diabetes control.

Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes, while the higher-dose version for obesity, Zepbound, gained FDA approval in late 2023. Like Ozempic, Mounjaro is sometimes prescribed off-label for weight loss, requiring appropriate documentation of the clinical rationale.

The Compounding Controversy

An important development in 2025: the FDA declared the semaglutide shortage resolved and effectively banned routine compounding of semaglutide for weight loss as of May 22, 2025. This decision significantly impacted telehealth companies that had been offering lower-cost compounded versions.

The ban exists because compounded medications lack the same FDA oversight as approved drugs, raising safety and quality concerns. If you encounter a telehealth provider offering ‘compounded semaglutide,’ this is a red flag. Legitimate providers now prescribe only FDA-approved, pharmacy-dispensed versions of these medications.

Prescribing Protocols

Initial Prescription: First prescriptions are typically for 4 weeks (one month) to assess how you tolerate the medication. This allows your provider to monitor for side effects and adjust dosing if needed.

Ongoing Prescriptions: Once you’re stable on the medication, prescriptions may be written for 1-3 months at a time. Some states’ medical board guidelines suggest monthly refills for weight loss medications (a holdover from older diet pill regulations), so many telehealth programs err on the side of more frequent check-ins early in treatment.

No Federal Quantity Limits: Unlike controlled substances, there are no federal restrictions on how much of these medications can be prescribed at once. However, clinical best practice—and insurance requirements—typically limit supplies to 90 days maximum.

The Patient Evaluation Process: What to Expect

Reputable telehealth providers follow a thorough evaluation process that mirrors in-person care standards:

Medical History Review

You’ll complete a detailed questionnaire covering:

• Current height, weight, and weight history
• Previous weight loss attempts (diet, exercise, medications)
• Existing medical conditions (especially thyroid problems, gallbladder issues, pancreatitis history)
• Current medications and supplements
• Family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Mental health history
• Pregnancy status and plans

Live Video Consultation

A licensed provider will review your information and conduct a virtual examination, which typically includes:

• Discussion of your weight loss goals and challenges
• Review of any contraindications or risk factors
• Explanation of how the medication works
• Discussion of potential side effects
• Review of proper injection technique
• Development of a comprehensive treatment plan including diet and exercise

Laboratory Work

Depending on your state’s requirements and your individual health status, you may need baseline lab work including:

• Complete metabolic panel (kidney and liver function)
• Hemoglobin A1C (blood sugar control)
• Thyroid function tests
• Lipid panel

Some telehealth providers can order lab work at local facilities near you, making this convenient even in a virtual care model.

Informed Consent

You’ll receive detailed information about:

• Expected results (typically gradual weight loss of 5-15% over several months)
• Common side effects (nausea, constipation, diarrhea, fatigue)
• Serious but rare risks (pancreatitis, gallbladder problems, thyroid tumors)
• The importance of lifestyle changes alongside medication
• Out-of-pocket costs if insurance doesn’t cover the medication

Eligibility: Who Qualifies for GLP-1 Weight Loss Medications?

Clinical Criteria

FDA approval and clinical guidelines establish clear eligibility requirements:

BMI ≥30: Adults with obesity (BMI of 30 or higher) generally qualify for weight loss medication treatment.

BMI ≥27 with Comorbidities: Adults who are overweight (BMI 27-29.9) qualify if they have at least one weight-related health condition such as:

• Type 2 diabetes or prediabetes
• High blood pressure
• High cholesterol
• Obstructive sleep apnea
• Cardiovascular disease

Prior Lifestyle Efforts: Most providers expect that you’ve attempted diet and exercise modifications before prescribing medication, though this isn’t an absolute requirement if there are medical reasons that make lifestyle changes alone insufficient.

Who Should NOT Take GLP-1 Medications

These medications are contraindicated for people with:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Current pregnancy or plans to become pregnant within 2 months
• History of severe pancreatitis
• Active gallbladder disease
• Severe gastroparesis or gastrointestinal disorders
• Known allergy to semaglutide or tirzepatide

Age Considerations

These medications are FDA-approved for adults 18 and older. Some formulations have been approved for adolescents (age 12+) with obesity in specific circumstances, but telehealth prescribing for minors involves additional considerations and may not be available through all platforms.

Ongoing Monitoring and Follow-Up

Telehealth weight loss treatment isn’t ‘prescribe and forget’—quality providers maintain regular contact:

Follow-Up Schedule

First Month: Expect a check-in within 2-4 weeks of starting medication to assess tolerance, side effects, and early response.

Months 2-6: Follow-ups typically occur every 4-8 weeks during the initial treatment period. Your provider will track your weight loss progress, adjust dosing, and address any concerns.

Long-Term: Once you’re stable on a maintenance dose, follow-ups may extend to every 2-3 months, though some states (like Florida) legally require at least quarterly visits.

What Happens During Follow-Ups

• Weight and BMI tracking
• Side effect assessment and management strategies
• Dose titration (gradually increasing dose per FDA-approved schedule)
• Review of diet and exercise progress
• Discussion of any new medications or health changes
• Lab work monitoring (periodically checking metabolic function)

State-Mandated Follow-Up Requirements

As mentioned earlier, some states have specific rules:

• Florida: At least one follow-up every 3 months
• Virginia: Initial follow-up within 30 days of starting therapy
• New Jersey: Regular monitoring as part of comprehensive weight management program

Red Flags: How to Identify Questionable Telehealth Services

Unfortunately, the popularity of these medications has attracted some less-than-reputable operators. Watch out for these warning signs:

Prescription Guarantees

Red Flag: Any service that guarantees you’ll get a prescription before evaluation.

Why It Matters: Legitimate providers must assess whether you’re a good candidate. Not everyone qualifies, and ethical providers will decline to prescribe if it’s not appropriate for you.

Compounded or ‘Generic’ Versions

Red Flag: Offers for compounded semaglutide, ‘generic Wegovy,’ or medications from overseas pharmacies.

Why It Matters: As of 2025, compounding of these medications for routine weight loss is banned by the FDA. Generic versions don’t yet exist (patents are still active). Overseas medications bypass FDA safety oversight.

No Real Consultation

Red Flag: Services that only require a brief questionnaire with no live provider interaction.

Why It Matters: Telehealth prescribing requires establishing a valid patient-provider relationship. This means actual communication with a licensed clinician—typically via live video.

Minimal Follow-Up

Red Flag: No scheduled follow-ups or monitoring after the initial prescription.

Why It Matters: These are powerful medications that require ongoing oversight for safety and effectiveness. The standard of care includes regular check-ins.

Unclear Provider Credentials

Red Flag: No transparency about who the prescribing providers are, what states they’re licensed in, or their qualifications.

Why It Matters: Your provider must be licensed in your state. You have a right to know who’s responsible for your care.

Pressure Tactics or Unrealistic Claims

Red Flag: Promises of dramatic weight loss, claims that ‘everyone loses 50 pounds,’ or pressure to start immediately.

Why It Matters: Results vary significantly between individuals. Ethical providers set realistic expectations (typically 10-15% body weight reduction over 6-12 months) and never rush you into treatment.

Cost and Insurance Considerations

Insurance Coverage

Insurance coverage for GLP-1 weight loss medications varies widely:

Medicare: Traditional Medicare Part D does not cover medications prescribed solely for weight loss (this is a legislative restriction). However, if you have diabetes, Ozempic or Mounjaro prescribed for diabetes management may be covered.

Commercial Insurance: Many private insurers have added coverage for Wegovy and Zepbound, but often with strict requirements:

• Prior authorization demonstrating medical necessity
• Documented BMI meeting threshold
• Evidence of previous lifestyle modification attempts
• Sometimes required counseling or supervised diet program

Medicaid: Coverage varies dramatically by state. Some states cover these medications; others specifically exclude them.

Out-of-Pocket Costs

Without insurance coverage:

• Wegovy: $1,300-$1,500 per month
• Ozempic: $900-$1,000 per month
• Mounjaro/Zepbound: $1,000-$1,200 per month

Manufacturer Savings Programs: Both Novo Nordisk (maker of Wegovy/Ozempic) and Eli Lilly (maker of Mounjaro/Zepbound) offer savings cards that can reduce costs significantly for eligible patients with commercial insurance. These programs may bring costs down to $25-$100 per month.

Telehealth Service Fees

In addition to medication costs, telehealth services typically charge:

• Initial Consultation: $50-$200
• Follow-Up Visits: $40-$100 per visit
• Monthly Program Fees: Some services charge $99-$300/month for ongoing care coordination, prescription management, and provider access

Klarity Health Advantage: We accept both insurance and cash pay, with transparent pricing and no hidden fees. Our providers are available across multiple states, making it easier to access care regardless of where you live.

Privacy and Data Security

Telehealth for weight loss involves sharing sensitive information. Reputable providers must comply with:

HIPAA (Federal)

The Health Insurance Portability and Accountability Act requires healthcare providers to protect your medical information through:

• Encrypted video platforms
• Secure messaging systems
• Protected health record storage
• Limited data sharing (only with your consent)

State Privacy Laws

Several states have enacted additional privacy protections:

Washington’s My Health My Data Act (2023) imposes strict requirements on how health data—including weight, biometric data, and health conditions—can be collected, used, and shared. Telehealth providers serving Washington residents must comply with explicit consent requirements.

California Consumer Privacy Act (CCPA) gives patients additional rights to know what data is collected and request deletion.

What to Verify

Before using a telehealth service, confirm:

• They use HIPAA-compliant video platforms (not just FaceTime or basic Zoom)
• They have a clear privacy policy explaining data use
• They don’t sell your health data to third parties
• You can request a copy of your records
• You can request deletion of data (with some exceptions for required medical records)

How Klarity Health Makes Telehealth Weight Loss Care Simple

At Klarity Health, we’ve built our platform specifically to address the challenges and concerns outlined in this guide:

Provider Network

We work with licensed MDs, DOs, NPs, and PAs across multiple states, ensuring you can connect with a qualified provider regardless of where you live. All our providers are credentialed, experienced in obesity medicine, and stay current on state-specific requirements.

Transparent Process

• Clear Eligibility: We explain upfront what’s required to qualify for treatment
• Honest Assessment: Our providers will only prescribe if it’s clinically appropriate for you
• Real Consultations: Live video visits with licensed clinicians, not just questionnaires
• Regular Follow-Up: Structured monitoring to track your progress and ensure safety

Both Insurance and Cash Pay Options

We accept insurance where coverage is available and offer transparent cash-pay options when it’s not, so cost is never a complete barrier to care. We’ll help you explore manufacturer savings programs and other ways to make treatment affordable.

Comprehensive Support

Beyond just prescriptions, we provide:

• Nutrition and lifestyle coaching resources
• Injection training and technique support
• Side effect management guidance
• Coordination with your local pharmacy
• Connection to your primary care provider when appropriate

Privacy First

We use enterprise-grade security, HIPAA-compliant platforms, and never sell your data. Your weight loss journey is personal, and we treat your information with the confidentiality it deserves.

Looking Ahead: The Future of Telehealth Weight Loss Care

The regulatory landscape continues to evolve in favor of expanded access:

Federal Developments

• The DEA’s telehealth flexibilities for controlled substances have been extended through December 31, 2025, with strong signals pointing toward further extensions or permanent rules in 2026
• Congressional bills like the TREATS Act aim to permanently preserve telehealth access for certain medications
• Medicare coverage expansions for obesity counseling (though not yet the medications themselves) indicate growing federal recognition of obesity as a serious medical condition requiring treatment

State Trends

• More states are granting nurse practitioners full practice authority, expanding the provider workforce for telehealth care
• Interstate medical licensure compacts are making it easier for providers to serve patients across state lines
• States are increasingly aligning telehealth standards with in-person care rather than imposing extra restrictions

Clinical Advances

New obesity medications are in development, and as the field expands, telehealth will likely become even more central to ensuring broad access. The success of current GLP-1 programs demonstrates that remote monitoring and management can be both safe and effective for appropriate patients.

Getting Started: Your Next Steps

If you’re considering telehealth for weight loss medication:

1. Verify Your Eligibility

Calculate your BMI and review whether you meet the clinical criteria (BMI ≥30, or ≥27 with comorbidities).

2. Check Your State’s Requirements

Review the state-specific table earlier in this guide to understand any special requirements where you live.

3. Gather Your Information

Before your consultation, have ready:

• Current medications list
• Medical history, especially thyroid, pancreas, and gallbladder issues
• Recent weight history
• Previous weight loss attempts

4. Choose a Reputable Provider

Look for services that:

• Clearly display provider credentials
• Offer live video consultations
• Have transparent pricing
• Include ongoing monitoring
• Are HIPAA-compliant

5. Schedule a Consultation

Ready to explore whether telehealth weight loss treatment is right for you? Klarity Health makes it easy to connect with a licensed provider who can evaluate your needs and develop a personalized treatment plan. Our team is experienced in navigating state requirements, insurance coverage, and the clinical nuances that make your weight loss journey successful.

Book a consultation with Klarity Health to take the first step toward sustainable weight management with expert support, transparent pricing, and care that fits your life.

Frequently Asked Questions

Is telehealth weight loss treatment covered by insurance?

Coverage varies by insurance plan. Many commercial insurance plans now cover medications like Wegovy when prescribed for obesity (BMI ≥30 or ≥27 with comorbidities), often requiring prior authorization. Medicare Part D does not cover weight loss medications, though it may cover the same drugs when prescribed for diabetes. Klarity Health can help you navigate your insurance benefits and explore alternative payment options if needed.

How long do I need to stay on these medications?

GLP-1 medications for weight loss are designed for long-term use. Most people maintain them for at least 12-18 months, and some remain on therapy indefinitely. Clinical studies show that weight regain is common when the medication is stopped, which is why ongoing treatment paired with lifestyle changes offers the best results. Your provider will work with you to determine the right duration based on your response and goals.

What happens if I move to a different state during treatment?

Your provider must be licensed in the state where you’re physically located during consultations. If you move permanently, you’ll need to connect with a provider licensed in your new state. Many telehealth platforms, including Klarity Health, have providers in multiple states to make this transition smoother. Inform your provider as soon as you know you’re relocating so arrangements can be made.

Can I get a prescription for my teenager through telehealth?

Some GLP-1 medications have FDA approval for adolescents aged 12 and up with obesity, but telehealth prescribing for minors involves additional requirements and may not be available through all platforms. Typically, pediatric obesity treatment requires more intensive monitoring and often coordination with a pediatrician. Contact the telehealth provider directly to understand their policies for patients under 18.

What if I experience side effects?

Common side effects like nausea, constipation, or mild stomach upset often improve after the first few weeks as your body adjusts. Your telehealth provider should be available for consultation if you experience troublesome side effects—dose adjustment or temporary treatment pause may help. Serious symptoms like severe abdominal pain, persistent vomiting, or signs of pancreatitis require immediate medical attention (call 911 or go to an emergency room). Quality telehealth services provide clear guidance on when to seek urgent care.

References

This article was researched and verified using authoritative sources as of December 17, 2025. Key references include:

1. Drug Enforcement Administration. ‘DEA and HHS Extend Telemedicine Flexibilities through 2025.’ Official announcement, November 15, 2024. www.dea.gov

2. Axios News. ‘COVID-era telehealth prescribing extended for controlled substances.’ November 18, 2024. www.axios.com

3. McDermott Will & Emery LLP. ‘DEA Extends Telemedicine Flexibilities for Controlled Substance Prescribing Through December 31, 2025.’ Legal analysis, November 18, 2024. www.mwe.com

4. Goodwin Procter LLP. ‘The Changing Regulatory and Reimbursement Landscape for GLP-1 and Other Weight-Loss Drugs.’ Client alert, March 27, 2024. www.goodwinlaw.com

5. Reuters. ‘Telehealth firm Hims to cut 4% of workforce amid ban on weight-loss drug copies.’ May 30, 2025. www.reuters.com

Additional verification was conducted through state medical board websites, FDA guidance documents, and clinical practice guidelines current as of December 2025. Federal telehealth rules for controlled substances are subject to extension beyond December 31, 2025; readers should check current status for the most up-to-date information.

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20,year%20extension
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=telemedicine%20flexibilities%20through%20December%2031%2C,HHS%20on%20November%2015%2C%202024
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=,a%20final%20set%20of%20regulations
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=31%2C%202024.%20,In%20February%202023%2C%20the%20DEA
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=to%20perform%20an%20in,rule%20regarding%20telemedicine%20prescribing%20of
• https://www.whitehouse.senate.gov/news/release/whitehouse-murkowski-warner-blackburn-urge-white-house-and-dea-to-extend-telehealth-flexibilities-for-substance-use-disorder-and-mental-health-treatment/#:~:text=Whitehouse%2C%20Murkowski%2C%20Warner%2C%20Blackburn%20Urge,substance%20use%20disorder%20treatment%20Washington
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,person%20examination
• https://www.nextech.com/blog/semaglutide-laws-by-state#:~:text=Who%20can%20prescribe%20semaglutide%3F%20,
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,encounter%20to%20establish%20a%20valid